Comparison · NCT02477696-5ebe5490
Acalabrutinib vs Ibrutinib: Number of Participants With Treatment-emergent Infections Grade >= 3
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Acalabrutinib vs Ibrutinib: Number of Participants With Treatment-emergent Infections Grade >= 3. Trial comparisons, record NCT02477696-5ebe5490. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02477696-5ebe5490
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.368 | 0.313 | 0.428 | wilson | |
| Risk in group 2 | 0.384 | 0.327 | 0.444 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0156 | -0.0975 | 0.0666 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.959 | 0.77 | 1.19 | log | |
| Odds ratio, group 1 over group 2 | 0.936 | 0.658 | 1.33 | log | |
| Number needed to treat, for one fewer participant with the outcome on Acalabrutinib than on Ibrutinib | 64.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Acalabrutinib | Participants received oral acalabrutinib (ACP196) 100 mg BID until PD, or unacceptable toxicity, or other reasons for discontinuation, whichever occurred first. | 98 | 266 | OG000 |
| Group 2 | Ibrutinib | Participants received oral ibrutinib 420 mg QD until PD, or unacceptable toxicity, or other reasons for discontinuation, whichever occurred first. | 101 | 263 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Treatment-emergent Infections Grade >= 3
- Description
- Number of participants with treatment-emergent infections Grade \>=3 are reported.
- Time frame
- Day 1 through 83.5 months (maximum observed duration)
- Population
- Safety population included all participants who received at least one dose of study drug and were analyzed as treated.
Source ClinicalTrials.gov
Trial
- Title
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
- NCT number
- NCT02477696
- Phases
- PHASE3
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Acalabrutinib, Ibrutinib
- Lead sponsor
- Acerta Pharma BV
- Results first posted
- 2022-01-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02477696?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02477696-5ebe5490